A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Ligelizumab (Primary) ; Omalizumab
- Indications Urticaria
- Focus Registrational; Therapeutic Use
- Acronyms Pearl 1
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 30 Jan 2019 Planned End Date changed from 20 May 2021 to 30 Apr 2021.
- 30 Jan 2019 Planned primary completion date changed from 22 May 2020 to 4 May 2020.
- 31 Oct 2018 Planned End Date changed from 30 Apr 2021 to 20 May 2021.